WEST LAFAYETTE, Ind., April 3, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that four poster presentations will be presented by Endocyte scientists at the 2013 Annual Meeting of the American Association for Cancer Research (AACR) to be held in Washington, D.C., April 6-10, 2013.
"Significant advances were made to our SDMC technology platform over the past year which collectively have led to the discovery of several new lead molecules that are currently in preclinical development," said Christopher Leamon, Ph.D., vice president of research and development. "We are excited to take part in this year's AACR meeting where we will discuss the applications of our pipeline compounds for cancer therapy."
Presentations are as follows:
|
Abstract #: |
2145 |
|
Title: |
"PSMA-specific anti-tumor activity of the targeted-tubulysin conjugate, EC1169" |
|
When: |
Monday, April 8, 1 p.m. – 5 p.m. EDT |
|
Session ID: |
Novel Targeted Therapies 1 |
|
Location: |
Hall A-C, Poster Section 40 |
|
|
|
|
Abstract #: |
4499 |
|
Title: |
"Total synthesis of tubulysins: A new chemical reaction leads to analogues with enhanced cytotoxicity" |
|
When: |
Tuesday, April 9, 1 p.m. – 5 p.m. EDT |
|
Session ID: |
Genome and Microtubule Integrity |
|
Location: |
Hall A-C, Poster Section 42 |
|
|
|
|
Abstract #: |
5623 |
|
Title: |
"Extracellular thiols and system xc play a significant role in non-targeted in vitro activity of a folate-tubulysin B conjugate" |
|
When: |
Wednesday, April 10, 8 a.m. – noon EDT |
|
Session ID: |
Novel Delivery Technologies |
|
Location: |
Hall A-C, Poster Section 41 |
|
|
|
|
Abstract #: |
5502 |
|
Title: |
"Vintafolide: a first-in-class small molecule drug conjugate targeting folate receptor positive tumors" |
|
When: |
Wednesday, April 10, 8 a.m. – noon EDT |
|
Session ID: |
Chemotherapy and Cancer Dependencies |
|
Location: |
Hall A-C, Poster Section 37 |
About Endocyte
Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.
For additional information, please visit Endocyte's website at www.endocyte.com.
CONTACT: Stephanie Ascher
Stern Investor Relations, Inc.
(212) 362-1200
stephanie@sternir.com
Martina Schwarzkopf, Ph.D.
Russo Partners
(212) 845-4292
martina.schwarzkopf@russopartnersllc.com
Tony Russo, Ph.D.
Russo Partners
(212) 845-4251
tony.russo@russopartnersllc.com
